Index

A
Abdominal hysterectomy, 273
ACUFLUSH study, 93
Acupuncture, 93
Adult Treatment Panel of the National Cholesterol Education Program (ATP-NCEP), 18
AI-associated bone loss (AIBL), 288, 289
Alopecia. See Hair loss
American Society of Clinical Oncology (ASCO) treatment guidelines, 291
Androgen deprivation therapy, 14, 291
Androgen receptors (AR), 188
Androgens
breast cancer, 188–189
case presentation, 173
FADS, 176–178
physiology
after hysterectomy and oophorectomy, 176
ovaries and adrenal glands, 173–174
total and free testosterone levels, age, 174, 175
testosterone (see Testosterone supplementation)
Antiresorptive therapy, 291, 293
Aromatase inhibitors [AI] therapy, 286, 288–289, 293
AZURE randomized open-label phase 3 trial, 293

generic predisposition to ovarian cancer, 231
symptoms, 230
TOA, 231
Bipolar disorder, 114
Bisphosphonates
ABCSG-12, 289
AIBL, 289
in clinical practice, 289, 292
contraindication, 294
drug-specific, 292, 294
E-ZO-FAST, 289
immediate or prophylactic therapy versus delayed therapy, 289
management strategy, 291, 293
risks and benefits, 293
treatment guidelines, 290–291
Z-FAST, 289
ZO-FAST, 289
zoledronic acid, 289
Bone mineral density (BMD), 223
assessment, 147
breast cancer, 286
DXA, 146–148
oral bisphosphonates, 291
postmenopausal estrogen use, 19
Botanical treatments, 96–97
Bothersome vasomotor symptoms
biochemical testing, 250
carcinoid syndrome, 246–248
diaphoresis, hypertensive assessment, 245–246
diagnosis, 245–246
transdermal estrogen therapy, 245
genetic testing, 249
hereditary syndrome, 250
medical conditions, 247, 248
obese with type 2 diabetes mellitus, 239–244
Bothersome vasomotor symptoms (cont.)
- pheochromocytomas, 248, 249
- thyroid hormone excess, 246

Breast cancer, 73
- aromatase inhibitors, 260
- BRCA1 and BRCA2 gene mutations, 259
- chemoprophylaxis, 260
- diagnosis, 258–259
- disease stage, 304
- endometrial evaluation, 260
- estrogen deficiency, symptoms of, 261
- hormonal therapy, 259
- management, 304
- ovarian ablation (surgical/radiation), 261
- ovarian suppression strategies, 261
- pathology, 304
- patient management, 256
- pharmacological therapy
- quality of life, 304
- raloxifene, 259–260
- risk factors, 258
- sexual function effects
  - chemotherapy-related neuropathies, 305–306
  - FSD, 305
  - hormonal interventions, 308–311
  - iatrogenic factors, 306–308
  - nonhormonal therapies, 311–315
  - on relationships and partners, 306
  - sexual pain disorders, 305
  - symptoms, 306
  - vaginal dryness, 305
- tamoxifen, 259

Conjugated equine estrogen (CE), 14
Continuous positive airway pressure (CPAP), 120
Coronary artery disease (CAD), 15–18, 20, 21, 24
Coronary heart disease (CHD), 71, 267
Cowden syndrome, 259

D
- Denosumab, 294–295
- Dual-energy X-ray absorptiometry (DXA), 146

E
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 293
- Endometrial cancer, 73, 275–276, 281
- Endometrial stromal sarcoma (ESS), 280–281
- Endometrioid endometrial cancer, 273
- Endometriosis, 231–232
- Epithelial ovarian cancer, 276–278
- Epworth Sleepiness Scale, 115
- European Society for Medical Oncology (ESMO) guidelines, 291
- Eysenck’s Personality Inventory, 94

F
- Female androgen deficiency syndrome (FADS), 176–178
- Female pattern hair loss (FPHL) of all ages, 198
- alopecia areata, 202
- anagen hair follicle, 199, 200
- chemotherapeutic agents, 201
- crown of scalp, 199–201
- diagnosis, 199
- differential diagnosis, 202
- frontal fibrosing alopecia, 202
- LPP, 202
- medications, 201
- nonmedical treatment option, 204
- ovarian estrogen production, 199
- precipitating events, 200
- prevalence, 199
- psychotropic agents, 201
- telogen effluvium, 200, 201
- topical minoxidil, 203, 205
- Female sexual function disorder (FSD), 305
- definition, 305
- iatrogenic factors
  - aromatase inhibitors, 307–308
  - dyspareunia, 307
  - endocrine therapies, 306

C
- Camouflage techniques, 204
- Carcinoid syndrome, 246–248
- Cardiometabolic effects
  - body fat distribution, 186
  - insulin resistance, 186–187
  - lipid profile, 187–188
  - vasculature, 188
- Cervical cancer, 274, 279
- Chronic endocrine therapy, 291
- Climacteric symptoms (CBT-C), 117
- Cognitive behavioral therapy for insomnia (CBT-I), 116–117
- Cognitive behavior therapy (CBT), 96
- Combination oral contraceptive pill (COCPR), 214
- Complementary and alternative medicine (CAM) therapies, 266–267
- Compounded bioidentical HT (CBHT), 74, 78–79
- Congenital adrenal hyperplasia (CAH), 213
- Denosumab, 294–295
- Dual-energy X-ray absorptiometry (DXA), 146

Index
raloxifene, 307
tamoxifen, 306, 307
nonhormonal therapies, 311–315
pelvic floor physical therapy, 311–315
Ferriman–Gallwey (FG) scoring system, 211
Flibanserin, 169
FPHL. See Female pattern hair loss (FPHL)
Fracture risk assessment tool (FRAX), 147, 288–291
FSD. See Female sexual function disorder (FSD)

G
γ-Aminobutyric acid (GABA)ergic medications, 49–51
Generalized anxiety disorder (GAD), 114
Genitourinary syndrome of menopause (GSM), 166
differential diagnosis
atrophic vaginitis, 132
contact dermatitis, 133
lichen planus, 133–134
lichen sclerosus, 133
pelvic floor and bladder disorders, 134
UTI, 133
vulvodynia, 134–135
estrogen deficiency, 139
estrogen products, 131–132
hormonal therapies
daily vaginal DHEA, 139
low-dose local vaginal estrogen formulations, 136, 137
pharmacological considerations, 139
SERM, 138
idiopathic vulvodynia, 141
low-dose local estrogen therapies, 131–132
management, 131
nonhormonal moisturizers and lubricants, 131–132
nonhormonal therapies, 135–136
oral ospemifene, 131–132
patient management, 139
quality of life, 140
sexual pain, 129
symptom severity, 140
urinary tract infections, 130
UTI recurrence, 140
vaginal dryness, 129
vulvovaginal atrophy, 131
Genitourinary syndrome of menopause (GUSM), 4–5, 8
Gonadotropin-releasing hormone (GnRH), 45
Gonadotropin-releasing hormone analogues (GnRHa), 215
Granulosa cell tumors (GCTs), 278–279
Greene Climacteric Scale, 94
GSM. See Genitourinary syndrome of menopause (GSM)
Gynecologic cancers, 274–275

H
Hair cycle, 198
Hair loss
Camouflage techniques, 204
case presentation, 197
finasteride, 204
follicles, 198, 199
FPHL (see Female pattern hair loss (FPHL))
hair cycle, 198
management, 197–198
scarring and non-scarring alopecias, 198
spironolactone, 203
topical and injectable steroids, 204
vitamin D, 203
Hashimoto’s thyroiditis, 221
Heart and Estrogen/Progestin Replacement Study (HERS), 16, 20–21
Hirsutism
case management and outcomes, 216–217
case presentation, 209–210
cosmetic therapies, 215–216
definition, 210
differential diagnosis, 212–213
follow-up, 217
history, 211
imaging, 212
laboratory testing, 212
management, 213–214
modified FG scale, 211
pharmacotherapy, 214–215
physical examination, 211
prevalence, 210
regional variation, 210
surgery, 216
Hormone replacement therapy (HRT)
with cervical cancer, 279
with endometrial cancer, 275–276, 281
with epithelial ovarian cancer, 276–278
with GCTs, 278–279
with gynecologic cancers, 274–275
synthetic hormone-like formulations, 310
systemic HT, 308–309
topical hormonal therapies, 310–311
with uterine mesenchymal tumors, 279–281
Hypoactive sexual desire disorder (HSDD), 179, 189
I
Insomnia, 107, 111
Insomnia Severity Index (ISI), 115

K
Kronos Early Estrogen and Progesterone Study (KEEPS), 26, 29, 32
Kronos Early Estrogen Prevention Study (KEEPS), 71, 233

L
Lichen planopilaris (LPP), 202
Li-Fraumeni syndrome, 259
Luteinizing hormone (LH), 45–46

M
Major depressive disorder (MDD), 114
Menopausal hormone therapy (MHT), 214
bothersome vasomotor symptoms, 262–263
breast cancer, 73
cognition and mood, 72–73
contraindications, 67, 68
coronary heart disease, 71
duration, 74
endometrial cancer, 73
evidence-based approach
  breast and bleeding concerns, 77–78
  initiate MHT, 77
  surgical menopause, 74–75
  symptomatic, 75–76
  unregulated CBHT, 74, 78–79
general principles, 70–71
indications
  osteoporosis, 69
  vasomotor symptoms, 68–69
  VVA, 69
joint and muscle pains, 73
management strategies and options, 166
post WHI
  cognition and memory, 31–32
  experimental studies, 25
  fracture risk reduction, 32
  gap theory, 28
  novel basic and clinical research, 24
  observational studies, 24, 25
  origins and evolution of, 27–28
  osteoporosis, 32
  progestins role, 28–29
  randomized controlled trials, 24
  stroke, 30–31
  timing hypothesis, 25–27
  VTE, 31
premature menopause, 73
pre-WHI, estrogen use
  coronary benefits, 15
  early years, 14–15
  PEPI trial, 17
public health, 18
secondary prevention trials, 20–21
skeletal benefits, 19–20
stroke risks, 16
quality of life, 73
sexual function, 73
sleep, 73
sleep disturbance, 118–119
stroke, 71
surgical menopause, 74–75
symptomatic, 75–76
tibolone, 69–70
TSEC, 70
type 2 diabetes mellitus, 72, 74
VTE, 72
WHI, 21–23

MHT. See Menopausal hormone therapy (MHT)

Mind-body techniques, 95–96
Mindfulness-based stress reduction (MBSR), 96, 118

N
NIH Revitalization Act, 14
Nonhormonal pharmacotherapies
  ADHD, 61
  breast cancer, 311–315
cost, 59
effective dosing, 52, 54
vs. estrogen, 52, 53
genetic risk, 60
GnRH, 45–46
hormonally sensitive cancer, 59–60
vs. hormonal therapy benefits, 57
hot flash management, 47
hypertension, 61
KNDy neuronal activity, 45–46
luteinizing hormone, 45–46
menopausal hot flash etiology, 46
opioid dependence, 61
osteoporosis, 60
pain, 60–61
restless legs syndrome, 61
side effects, 57–58
VMS
clonidine, 51–52, 59
GABAergic therapies, 49–51, 58–59
mood, 53
quality of life, 56, 57
serotonergic medications, 47–49, 58
sexual function, 54–56
sleep, 54, 56
SNRIs/SSRIs, 47–49
weight gain, 56–57

Non-rapid eye movement (NREM) sleep, 106

O
Obstructive sleep apnea (OSA), 112, 241
Ospemifene, 167
Osteoporosis, 60
bisphosphonates
ABCSG-12, 289
AIBL, 289
in clinical practice, 289, 292
contraindication, 294
drug-specific, 292, 294
E-ZO-FAST, 289
immediate or prophylactic therapy versus delayed therapy, 289
management strategy, 291, 293
risks and benefits, 293
treatment guidelines, 290–291
Z-FAST, 289
ZO-FAST, 289
zoledronic acid, 289
case presentation, 285–286
denosumab, 294–295
diagnosis, 286
DXA testing, 287
FDA-approved drugs
bisphosphonates, 155–156
calcitonin, 153
denosumab, 156–157
estrogen agonist/antagonist, 154
hormone replacement therapy, 153–154
odanacatib, 158
romosozumab, 158
strontium ranelate, 158
teriparatide, 157
tissue-selective estrogen complex: conjugated estrogens/bazedoxifene, 154–155
FRAX, 288–291
lifestyle and dietary interventions, 288
parental hip fracture, 296
raloxifene, 295–296
risk factors
BMD, 286
fragility fracture, 287
tamoxifen, 286–287
Ovarian cancer, genetic predisposition, 231

P
Panic disorder, 112, 114
Parathyroid hormone-related protein (PTHrP), 286
Patient Health Questionnaire, 169
Pelvic floor physical therapy
antidepressants, 315
biofeedback, 312
black cohosh (Cimicifuga racemosa), 313–314
combination herbal remedies, 314–315
dilator therapy, 312
herbal remedies, 312
pelvic organ prolapse, 311
physical therapy programs, 311
phytoestrogens, 312–313
urinary incontinence, 311
vaginal dilators, 312
Pelvic inflammatory disease (PID), 231
Perceived Stress Scale, 94
Perimenopause and menopause management
calcium, 98
fiber, 98
fluids, 98
healthy fats, 98
integrative approaches
acupuncture, 93
botanical treatments, 96–97
mind-body techniques, 95–96
yoga, 94
movement, 99
nonhormonal pharmacotherapies
clonidine, 92–93
gabapentin, 91
SSRIs/SNRIs, 91, 92
physiologic changes, 97
STRAW stages, 88–89
Periodic limb movement disorder (PLMD), 113
Peutz-Jeghers syndrome, 259
Pharmacotherapy, 214–215
Pheochromocytomas, 248
Physiologic transdermal androgen therapy, 179
Pittsburgh Sleep Quality Index, 115
POI. See Primary ovarian insufficiency (POI)
perimenopause and menopause management, 91, 92
vasomotor symptoms, 47–49
VMS, 264–265
Sexual dysfunctions, 166, 169
Sexuality, breast cancer diagnosis hormonal and nonhormonal pharmacotherapies, 304
iatrogenic estrogen deficiency, 304
non-pharmacological approaches, 304
painful intercourse, 303
quality of life, 304
vaginal dryness, 303
Sexual pain disorders, 305
Skeletal fragility alcohol consumption, 152
calcium intake, 150
cigarette smoking, 152
clinical and laboratory evaluation, 149–150
diagnosis, 146–148
fall prevention programs, 152
pharmacologic therapy bisphosphonates, 155–156
calcitonin, 153
denosumab, 156–157
estrogen agonist/antagonist, 154
hormone replacement therapy, 153–154
odanacatib, 158
recommendations, 152–153
romosozumab, 158
strontium ranelate, 158
teriparatide, 157
tissue-selective estrogen complex: conjugated estrogens/bazedoxifene, 154–155
prevalence, 148–149
risk factors, 147, 148
vitamin D Intake, 151–152
Sleep disturbances antidepressants, 119, 120, 121
anxiolytics, 119
assessment, 115–117
benzodiazepines, 120, 121
case presentation, 106
CPAP, 120
gabapentin, 120, 121
medical disorders, 112
OSA, 112
PMD, 113
RLS, 112–113
urinary disturbances, 113
MHT, 118–119
mirtazapine, 120
non-benzodiazepine sedative hypnotics, 120, 121
non-pharmacological treatments, 116–118
physiology insomnia, 107, 111
lifespan, 106, 108
NREM, 106
REM, 106
stages, 106, 107
STRAW, 107, 109
SWS, 106
psychiatric disorders, 112
bipolar disorder, 114
GAD, 114
MDD, 114
panic disorder, 112, 114
PTSD, 115
reproductive hormones, 111
sedative hypnotics, 119
sleep-related burden and risk factors, 109–111
Slow-wave sleep (SWS), 106
Smooth muscle tumors of uncertain malignant potential (STUMP) tumors,
279–280
SNRIs. See Selective norepinephrine reuptake inhibitors (SNRIs)
Spielberger State-Trait Anxiety Scale, 115
SSRIs. See Selective serotonin reuptake inhibitors (SSRIs)
Stages of Reproductive Aging Workshop (STRAW), 7–8
perimenopause and menopause management, 88–89
sleep disturbances, 107, 109
Study of Women’s Health Across the Nation (SWAN), 181
Suppression of Ovarian Function Trial (SOFT), 261, 308

T Tamoxifen, 286–287
Tamoxifen and Exemestane Trial (TEXT), 261
Testosterone supplementation cardiometabolic effects body fat distribution, 186
insulin resistance, 186–187
lipid profile, 187–188
vasculature, 188
in postmenopausal women body composition, 181, 182
bone, 184
clinical trials, 180
Testosterone supplementation (cont.)
cognition, 181, 183
HSDD, 179
Intrinsa, 178
menopausal symptoms, 184–185
muscle performance, 181, 182
non-estrogen, 179
on-treatment total testosterone concentrations, 179–180
physical function, 180–181
physiologic transdermal androgen therapy, 179
sexual function, 179
undesired androgenic effects, 185–186
Testosterone therapy, 168
Thyroid hormone excess
antithyroid drugs, 246
laboratory evaluation, 246, 247
Timing hypothesis
emergence, 25–26
experimental testing, 26–27
Tissue-selective estrogen complex (TSEC), 70
Trabecular bone score (TBS), 288
Tubo-ovarian abscess (TOA), 231
Type 2 diabetes mellitus (T2DM)
avessment, 240
diagnostic criteria, 240
gabapentin therapy, 244
management, 242–243
non-hormonal strategy, 243–244
office-based screening, 241
OSA, 241
osteoporotic fractures, 242
overnight polysomnography, cardiac rhythm monitoring, 241
risks factors, 239
sleep apnea management, 241
testing criteria, prediabetes, 240, 241

U
Urinary disturbances, 113
Urinary tract infection (UTI), 133, 140
US Preventive Services Task Force (USPSTF), 146
Uterine mesenchymal tumors, 279–281
Uterine sarcomas, 279–281

V
Vasomotor symptoms (VMS), 165, 166, 169
hot flashes, 256

W
Women’s Estrogen for Stroke Trial (WEST), 16
Women’s Health Initiative (WHI), 21–23
Women’s Health Initiative Estrogen plus Progestin (WHI-EP) trial, 262
Wrist actigraphy, 115

Y
Yoga, 94